Compound class:
Synthetic organic
Comment: The chemical structure for glovadalen was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a dopamine D1 receptor positive allosteric modulator (PAM). It is claimed in UCB Biopharma's patent WO2021001288A1 [1]. Exploration of UCB's declared pipeline suggests that glovadalen may be their clinical lead UCB0022, that is being developed for Parkinson's disease [2]. We will update this entry when the structure for UCB0022 and/or glovadalen is published.
|
|
Download 2D Structure ![]() |
|
Canonical SMILES | Download |
Isomeric SMILES | Download |
InChI standard identifier | Download |
InChI standard key | Download |
Molecular structure representations generated using Open Babel